Dutasteride Research

5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis.

Yang Y, Hu H, Zhang H, Liu Z, Zhao F, Yang J · Urol J (2021)

Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.

Lee S, Lee YB, Choe SJ, Lee WS · Acta Derm Venereol (2019)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.

Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z · BMC Urol (2019)

Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.

Gupta AK, Mays RR, Dotzert MS, Versteeg SG, Shear NH, Piguet V · J Eur Acad Dermatol Venereol (2018)

Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.

Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M · Andrology (2017)

Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis.

Yin T, Qiao Z, Li Y, Li D, Jiang M, An C · Am J Ther (2017)

Even short durations (2 weeks) of 5ARI therapy can significantly reduce prostate vascularity.

The role of 5-alpha reductase inhibitors in transurethral resection of the prostate: a meta-analysis of randomised controlled trials

Hehir CM, Calpin GG, Cullivan O, Daly GR, Dowling GP, Davis NF. · BJU international (2026)

The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.

Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y · Clin Interv Aging (2019)

The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH.

Brown N, Kiosoglous A, Castree S, Firouzmand S, McBean R, Walker DG · BJU Int (2024)

Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.

Kramer JJ, Gu L, Moreira D, Andriole G, Csizmadi I, Freedland SJ · J Urol (2022)

Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial.

Kuhlmann PK, Fischer SC, Howard LE, Moreira DM, Andriole GL, Hopp ML · J Urol (2021)

Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.

Yamanishi T, Asakura H, Seki N, Tokunaga S · Urol Int (2021)

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.

D'Agate S, Wilson T, Adalig B, Manyak M, Palacios-Moreno JM, Chavan C · World J Urol (2020)

Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study.

Roehrborn CG, Rosen RC, Manyak MJ, Palacios-Moreno JM, Wilson TH, Lulic Z · Int J Clin Pract (2020)

Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity.

Busetto GM, Del Giudice F, Maggi M, Antonini G, D'Agostino D, Romagnoli D · Aging (Albany NY) (2020)

Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Allott EH, Csizmadi I, Howard LE, Muller RL, Moreira DM, Andriole GL · BJU Int (2020)

Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.

Schwarzman LS, Pagani RL, Ohlander SJ, Mima M, Abern MR, Andriole GL · Urology (2020)

Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.

Freitas D, Andriole GL, Freedland SJ, Neto BS, Moreira DM · Urology (2019)

A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).

Yamanishi T, Asakura H, Seki N, Tokunaga S · Low Urin Tract Symptoms (2019)

Computer vision detects subtle histological effects of dutasteride on benign prostate.

Sethi A, Sha L, Kumar N, Macias V, Deaton RJ, Gann PH · BJU Int (2018)